Clinical trials: thyroid
Hypothyroidism
Thyroid Function of Pediatric Subjects Following Isovue® Administration
This is a Phase IV prospective, multicenter, observational study to estimate the proportion of subjects 0 to 3 years of age who develop abnormal thyroid function after exposure to intravascular administration of ISOVUE for the…
- Trial name
- NCT03779906
- Testing
- Isovue
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bracco Diagnostics, Inc
Thyroid Eye Disease
An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)
Multicentre, Phase Ib/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of NTB003 in Participants with Thyroid Eye Disease
- Trial name
- NCT07462130
- Testing
- NTB003
- Volunteers
- 74 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Hypothyroidism
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone [TSH])…
- Trial name
- NCT06345339
- Testing
- Armour Thyroid, Levothyroxine
- Where
- 139 sites in United States, Puerto Rico
- Volunteers
- 2,701 people
- Sponsor
- AbbVie
Total Thyroidectomy, Near-total Thyroidectomy
Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients
This study is designed as a combination of phase 1 (Part A) and phase 2 (Part B). The purpose of Part A was to determine the safety, tolerability, and pharmacokinetics in patients with total thyroidectomy or near total…
- Trial name
- NCT03276988
- Testing
- Period 1 GX-30, Period 2 THYROGEN®, Period 1 THYROGEN®, Period 2 GX-30
- Where
- 5 sites in South Korea
- Volunteers
- 8 people
- Sponsor
- Genexine, Inc.
Thyroid Eye Disease
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
- Trial name
- NCT06248619
- Testing
- Teprotumumab
- Where
- 38 sites in United States, Argentina and 9 more
- Volunteers
- 89 people
- Sponsor
- Amgen
Hypothyroidism
Observational Study With Prospective and/or Retrospective Follow-up, Without Modifying Patient Treatment and Follow-up Practices for the Initial Treatment of Hypothyroidism in France
This observational survey with prospective and/or retrospective follow-up is designed to study practices for the initial treatment of hypothyroidism in France without modifying subject treatment.
- Trial name
- ORCHIDEE (NCT01197183)
- Where
- France
- Volunteers
- 1,285 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Graves' Disease
A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease
An open label study to evaluate the safety and efficacy of CFZ533 following 12 weeks treatment in patients with Graves' disease
- Trial name
- NCT02713256
- Testing
- CFZ533
- Where
- 3 sites in United States, Germany
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Cancer, Metastatic Cancer
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma
- Trial name
- NCT05557045
- Testing
- JZP815
- Where
- 15 sites in United States
- Volunteers
- 98 people
- Sponsor
- Jazz Pharmaceuticals
Healthy Volunteers
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants
The primary objective of the study is to evaluate the pharmacokinetics (PK) of teprotumumab after a single intravenous (IV) infusion of teprotumumab in healthy Chinese participants.
- Trial name
- NCT07142642
- Testing
- Teprotumumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Amgen
Differentiated Thyroid Cancer
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Differentiated Thyroid Cancer.
- Trial name
- NCT02586337
- Testing
- Anlotinib
- Where
- 19 sites in China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Hypothyroidism
A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
ST-1891-201 is a multicenter, randomized, double-blind, partial crossover, Phase 2 study evaluating the safety and efficacy of hormone replacement therapy with ST-1891 compared to levothyroxine in patients with primary…
- Trial name
- NCT05412979
- Testing
- ST-1891, Levothyroxine
- Where
- 39 sites in United States
- Volunteers
- 490 people
- Sponsor
- Sention Therapeutics, LLC
Medullary Thyroid Cancer (MTC)
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
Background: GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA.
- Trial name
- NCT01856920
- Testing
- GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- NantCell, Inc.
Melanoma, Solid Tumor
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions…
- Conditions
- Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification
- Trial name
- NCT04985604
- Testing
- Tovorafenib
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 23 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Hyperthyroidism, Graves Disease
AI-Based Wearable Monitoring (Glandy HYPER) for Antithyroid Drug Dose Adjustment in Graves' Disease
Graves' disease is the most common cause of hyperthyroidism and is usually treated with antithyroid drugs such as methimazole (MMI).
- Conditions
- Hyperthyroidism, Graves Disease, Thyrotoxicosis
- Trial name
- NCT07857421
- Testing
- Glandy HYPER (AI-based monitoring software), Methimazole
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- THYROSCOPE INC.
Hypothyroidism
Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit
This is a Phase 4, single-center, open-label, interventional study, wherein all enrolled subjects will be tested for Thyroid Stimulating Hormone (TSH) by using the quantitative and the qualitative Point-of-Care (POC) TSH test…
- Trial name
- NCT01921452
- Testing
- Quantitative POC TSH Kit, Qualitative POC TSH Kit, Third generation TSH Kit
- Where
- China
- Volunteers
- 283 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Hypothyroidism
Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular iohexol (Omnipaque™), iodixanol (Visipaque™)…
- Trial name
- NCT03631771
- Testing
- Iohexol, Iodixanol, Iopromide
- Sponsor
- GE Healthcare
Thyroid
A Prospective, Single-arm, Multi-centre, Blinded, Observational, Diagnostic Accuracy Study With a Diagnostic Medical Product
After thyroid surgery, 0.6 to 4% of patients develop postoperative bleeding. 90% of this postoperative bleeding occurs within the first 48 hours.
- Trial name
- HEDOS (NCT04845867)
- Testing
- ISAR-M THYRO
- Where
- Germany
- Volunteers
- 1,470 people
- Sponsor
- ISAR-M GmbH
Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism
Clinical Evaluation of NeoPlex4 Assay and NeoPlex System
The purpose of this study is to assess the agreement of clinical performance between the proposed NeoPlex 4 assay and NeoPlex System and the comparator devices in clinical use in newborn screening programs for detection of T4…
- Conditions
- Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism, Cystic Fibrosis
- Trial name
- NCT01488721
- Where
- 3 sites in United States
- Volunteers
- 7,462 people, healthy volunteers welcome
- Sponsor
- Luminex Corporation